Aurinia Pharmaceuticals Inc. Debt Securities, Available-for-sale
Aurinia Pharmaceuticals Inc. (AUPH) had Debt Securities, Available-for-sale of $311.60 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2024-11-07
- 2024-09-30: Debt Securities, Available-for-sale $311.60M.
- 2024-06-30: Debt Securities, Available-for-sale $297.30M.
- 2024-03-31: Debt Securities, Available-for-sale $255.70M.
- 2023-12-31: Debt Securities, Available-for-sale $301.80M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2024-09-30 | $311.60M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $297.30M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $255.70M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $301.80M 10-Q · filed 2024-11-07 | |
| 2023-09-30 | $292.10M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $269.00M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $272.50M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $295.20M 10-K · filed 2024-02-15 | $295.50M 10-K · filed 2023-02-28 |
| 2022-09-30 | $376.60M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $388.40M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $277.40M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $215.00M 10-K · filed 2023-02-28 | $214.90M 10-K · filed 2022-02-28 |
| 2021-09-30 | $207.30M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $153.60M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $115.20M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |